GT 2394

Drug Profile

GT 2394

Latest Information Update: 22 Dec 2003

Price : $50

At a glance

  • Originator Gliatech (CEASED)
  • Class Obesity therapies; Small molecules
  • Mechanism of Action Histamine H3 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Obesity

Most Recent Events

  • 22 Dec 2003 Discontinued - Preclinical for Obesity in USA (unspecified route)
  • 17 May 2002 Gliatech has filed a petition for bankruptcy protection
  • 12 Dec 2000 Preclinical development for Obesity in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top